Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Holdings Lifted by Zions Bancorporation N.A.

Zions Bancorporation N.A. raised its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,577 shares of the medical equipment provider’s stock after purchasing an additional 621 shares during the quarter. Zions Bancorporation N.A.’s holdings in Intuitive Surgical were worth $5,687,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. International Assets Investment Management LLC grew its holdings in shares of Intuitive Surgical by 49,383.6% during the 3rd quarter. International Assets Investment Management LLC now owns 1,090,619 shares of the medical equipment provider’s stock valued at $535,788,000 after acquiring an additional 1,088,415 shares in the last quarter. Capital Research Global Investors bought a new stake in Intuitive Surgical during the 1st quarter worth approximately $374,390,000. Vanguard Group Inc. lifted its holdings in Intuitive Surgical by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after buying an additional 493,126 shares in the last quarter. Strategic Financial Concepts LLC lifted its holdings in Intuitive Surgical by 40,221.4% during the 2nd quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock worth $1,184,000 after buying an additional 265,461 shares in the last quarter. Finally, GQG Partners LLC acquired a new position in Intuitive Surgical during the 1st quarter worth $99,523,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Robert Desantis sold 188 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total value of $90,655.48. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,655,048.26. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Jamie Samath sold 269 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $539.89, for a total transaction of $145,230.41. Following the transaction, the insider now owns 8,757 shares in the company, valued at approximately $4,727,816.73. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Robert Desantis sold 188 shares of the company’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $482.21, for a total transaction of $90,655.48. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,655,048.26. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 91,178 shares of company stock valued at $45,897,071 over the last 90 days. 0.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on ISRG shares. BTIG Research set a $535.00 price target on Intuitive Surgical in a research note on Friday, October 18th. Robert W. Baird increased their target price on Intuitive Surgical from $503.00 to $565.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Mizuho raised their price objective on Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. JPMorgan Chase & Co. raised their target price on shares of Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Citigroup raised their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $513.74.

Intuitive Surgical Stock Performance

NASDAQ ISRG opened at $536.69 on Thursday. The firm’s fifty day moving average price is $496.95 and its two-hundred day moving average price is $455.65. The stock has a market cap of $191.16 billion, a PE ratio of 86.28, a PEG ratio of 5.28 and a beta of 1.39. Intuitive Surgical, Inc. has a fifty-two week low of $287.98 and a fifty-two week high of $542.59.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The company had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.01 billion. As a group, sell-side analysts predict that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.